Bentham Science Oncology Collection

 

THE COLLECTION INCLUDE ARTICLES FROM THESE JOURNALS

 

ccdt-flyer.jpg                   pra                    acamc.jpg  cmc.jpg                   cdt-6-1.jpg                      cpd-14-16.jpg

 

and many more eBooks…

✔ 130 Journals

✔ 7 Book Series

✔ 45 Books in Total 

 

FEATURES AND BENEFITS: 

♦ Access to over 10,000 scholarly articles covering more than 70 different types of cancers.

♦ Contents come from more than 100 Bentham Science Journals (40 journals indexed in JCR 2017 with impact factor rankings)

♦ Includes both; Original Research and Review Articles

♦ Research from leading institutions in USA, EUROPE, AUSTRALIA, JAPAN, CHINA and other regions

♦ Suitable for researchers in industry and academia wishing to keep updated with latest developments

♦ Easy access to institutions and individuals through IP-based authentication

♦ Access new Oncology Research included in this collection as soon as it is published

 

FLEXIBLE PACKAGES 

 Over 2,000 articles from 2017 and 2018
 Over 3,000 articles from the last 3 years 
 More than 10,000 articles from the last 10 years

 

Annual addition of over 1,000 new oncology related articles each year

Tailor-made packages available for pharmaceuticals companies, research institutes, universities, hospitals, clinical/academic societies, and corporations.

You can also send your librarian’s contact information to us at marketing@benthamscience.net  CC: hermain@benthamscience.net

 

 

To learn more about our Oncology Article Collection, please visit  our website: http://bit.ly/2t1KID2

 

 

Article by Disease | Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin

Bentham Oncology Collection| Oncology | Cervical Cancer

 

 

 

Abstract:

Background: Based on the structure of RC-121 (D-Phe-c (Cys-Tyr-D-Trp-Lys-Val-Cys)-Thr-NH2, – synthetic derivatives of somatostatin), some analogs were synthesized and tested for in vitro cytotoxic and antioxidant activity.

Objectives: The new analogs were modifyed at position 5 with Dap (diaminopropanoic acid), Dab (diaminobutanoic acid) and Orn and at position 6 with the unnatural amino acids Tle (t-leucine).

Methods: The in vitro cytotoxic effects of the substances were investigated against a panel of human tumor cell lines HT-29 (Human Colorectal Cancer Cell Line), MDA-MB-23 (Human Breast Cancer Cell Line), Hep G-2 (Human Hepatocellular Carcinoma Cell Line) and HeLa (cervical cancer cell line). The antioxidant capacities were tested by ORAC (Oxygen Radical Antioxidant Capacity) and HORAC (Hydroxyl Radical Averting Capacity) methods.

Results: All substances expressed significantly higher antioxidant capacity by comparison with galic acid and Trolox. All substances showed considerable antioxidant capacity as well. Compound 2T (D-Phe-c(Cys-Tyr-DTrp- Dap-Tle-Cys)-Thr-NH2)had the highest antioxidant effect. The compound 4T (D-Phe-c(Cys-Tyr-D-Trp- Orn-Tle-Cys)-Thr-NH2) displayed antiproliferative effect on HeLa cells with IC50 30 μM. The peptide analog 3T (D-Phe-c(Cys-Tyr-D-Trp-Lys-Tle-Cys)-Thr-NH2) exerted the most pronounced inhibition on the cell vitality up to 53%, 56% and 65% resp. against MDA-MB-23, Hep G-2, HeLa in the higher tested concentration.

Conclusion: the somatostatin analogs showed moderate influence on the vitality of different tumor cells and could be used in changing their pathology.

 

Read out more at: http://www.eurekaselect.com/node/161359/article

Article by Disease | Design, Synthesis, and Biological Evaluation of New Azole Derivatives as Potent Aromatase Inhibitors with Potential Effects against Breast Cancer

Bentham Oncology Collection | Oncology | Breast Cancer

 

Graphical Abstract:

Abstract:

Purpose: Some aromatase inhibitors are FDA-approved agents as first-line therapy in the treatment of endocrine-responsive breast cancer. In this study, we aimed to develop new azole derivatives with higher specificity and potency.

Methods: New aromatase inhibitors were designed by Molecular Operating Environment (MOE) software and synthesized in a one-step SN2 reaction. These compounds were characterized by melting point, 1H- and 13CNMR, elemental analysis and mass spectra. The in vitro and in vivo aromatase inhibition of these compounds was evaluated using the Estrone ELISA assay, and by measuring the inhibition of androstenedione-induced uterine hypertrophy. The selectivity of aromatase inhibition was investigated by the inhibition of ACTH stimulation on the plasma concentrations of aldosterone and cortisol.

Results: Docking simulations showed that four new azole derivatives could efficiently interact with enzyme active sites. The in vitro aromatase-inhibition assay showed that the compounds 1,3,5-tris(imidazol-1- ylmethyl)benzene (3b) and 1,3-Bis(imidazole-1- ylmethyl) benzene (3d) effectively inhibited aromatase, with IC50 values of 0.2 nM and 6.8 nM, respectively; these values were similar to known aromatase inhibitor letrozole (IC50 0.3 nM). The in vivo aromatase-inhibitory potency of compound 3b was similar to letrozole, although compound 3b acted more selectively.

Conclusion: This report introduced a new compound that can be considered as a new lead for further investigation to explore more-potent and more-selective aromatase inhibitors.

 

 

Read out more at: http://www.eurekaselect.com/node/159088/article

Article by Disease |Design, Synthesis and Anti-breast Cancer Activity of Some Novel Substituted Isoxazoles as Anti-breast Cancer Agent

Bentham Oncology Collection | Oncology | Breast Cancer

Graphical Abstract:

 

 

Abstract:

Methods: A novel series of isoxazole (S21-S30) derivatives were designed, synthesized and screened for their anticancer activity against estrogen receptor-positive MCF-7 and negative MDA-MB-435 breast cancer cell lines. The synthesized derivative has the ability to inhibit the growth of the human breast cancer cell line at low concentrations. In vivo anticancer activity was performed on virgin female sprague dawley rats.

Results: The result shows that compound S23 has more selectivity and marked estrogen modulator activity than the standard tamoxifen.

 

Article by Disease |Study about How A Sample of Portuguese People Perceive the Health Benefits of Dietary Fibre

Bentham Oncology Collection | Oncology | Bowel Cancer

 

Graphical Abstract:

 

Abstract:

Background: Dietary Fibre (DF) has been part of human diet since ever, and its benefits for the human health have been well established and scientifically confirmed. However, it is important to study to what extent people are aware of those benefits.

Objective: Having in mind the importance of DF the present work was undertaken to study the level of knowledge of people residing in Portugal about the health effects related to DF.

Methods: A descriptive cross-sectional study was undertaken on a non-probabilistic sample of 382 adult participants. Descriptive statistics were used together with some inferential tests, all using the software SPSS and considering a level of significance of 5%.
Results: The results allowed concluding that people were differently informed about the effects of DF in preventing and/or treating various diseases, being constipation the most recognized, followed in decreasing order by obesity, bowel cancer, cholesterol, cardiovascular diseases, diabetes and breast cancer. The results also showed that significant differences were encountered between age groups for most of the diseases evaluated, but not between genders, levels of education or living environments.
Conclusion: Generally, it was concluded that the participants in this study were relatively well informed about the roles of DF in preventing and/or treating several diseases.

Read out more at: http://www.eurekaselect.com/node/149164/article

Article by Disease | New Medical Strategies for Midgut Carcinoids

Bentham Oncology Collection | Oncology Carcinoid Tumours

 

Abstract:

Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.

 

Read out more at: http://www.eurekaselect.com/node/71224/article

 

%d bloggers like this: